Antiplatelet agents in complex medication therapy in diabetic foot disease
DOI: 10.32364/2587-6821-2020-4-7-457-462
K.A. Koreyba
Kazan State Medical University, Kazan, Russian Federation
The urgency of the problem concerning treatment of diabetic foot disease is due to the following reasons: pathogenesis ambiguity of this pathology, tendency to trophic defects relapse and increase in volume during the conservative treatment, resistance to conservative treatment, deterioration of the life quality of patients, treatment complexity and duration, and significant economic costs for treatment and rehabilitation. The patterns of complex medication therapy effects include insufficient evidence for most drugs, the lack of generally accepted regimens and the low efficacy of existing ones. Given the own experience and using a mathematical model, it was proved that the benefits of using Cilostazol as part of combined medication therapy regimen for patients with diabetic foot syndrome and stage IIA, IIB chronic limb ischemia according to the classification of Fontaine-Leriche-Pokrovsky. The need to adhere to National Clinical Guidelines was justified.
Keywords: diabetic foot syndrome, national clinical guidelines, disaggregants, pulse oximetry, chronic limb ischemia, oxygen saturation,outcomes assessment.
For citation: Koreyba K.A. Antiplatelet agents in complex medication therapy in diabetic foot disease. Russian Medical Inquiry. 2020;4(7):457–462. DOI: 10.32364/2587-6821-2020-4-7-457-462.
Acknowledgment
Editorial Board is grateful to ESKO PHARMA for the assistance in technical edition of this publication.
About the author:
Konstantin A. Koreyba — Cand. of Sci. (Med.), Associate Professor of the Department of Surgical Diseases, Head of the «Diabetic Foot» Center, Kazan State Medical University: 49, Butlerova str., Republic of Tatarstan, Kazan, 420012, Russian Federation; ORCID iD 0000-0002-0821-2249.
Contact information: Konstantin A. Koreyba, e-mail: korejba_k@mail.ru. Financial Disclosure: the author has no financial or property interest in any material or method mentioned. There is no conflict of interests. Received 10.09.2020, revised 24.09.2020, accepted 08.10.2020.
2. Bensman V.M. Surgery of purulent-necrotic complications of diabetic foot: A guide for physicians. M.: Medpractica-M; 2015 (in Russ.).
3. Blaisdell F.W. The pathophysiology of skeletal muscle and the reperfusion syndrome: a review. Cardiovasc Surg. 2002;10(6):620–630. DOI: 10.1016/s0967-2109 (02) 00070-4.
4. Federal Law of December 25, 2018 Nо. 489-FZ "On Amendments to Article 40 of the Federal Law" On Compulsory Health Insurance in the Russian Federation "and the Federal Law" On the Basics of Health Protection of Citizens in the Russian Federation "on Clinical Recommendations" (Electronic resource). URL: https://rg.ru/2018/12/28/klinika-dok.html (access date: 08.28.2020) (in Russ).
5. Patent RU2506894C1 "System of helping people with syndrome of diabetic foot". Date of publication: 20.02.2014. Bull. 5 (in Russ.).
6. Stupin V.A., Silina E.V., Koreyba K.A., Goryunov S.V. Diabetic foot syndrome (epidemiology, pathophysiology, diagnosis and treatment). M.: Litterra; 2019 (in Russ.).
7. National guidelines for the diagnosis and treatment of diseases of the arteries of the lower extremities. Angiology and vascular surgery. 2019;25(2, Suppl. 2) (in Russ.).
8. Conte M.S., Bradbury A.W., Kolh P. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg. 2019;58(1S):S1–S109.e33. DOI: 10.1016/j.ejvs.2019.05.006.
9. Iida O., Yokoi H., Soga Y. et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation. 2013;127;2307–2315. DOI: 10.1161/CIRCULATIONAHA.112.000711.
10. Iftikhar O., Oliveros K., Tafur A.J., Casanegra A.I. Prevention of femoropopliteal in-stent restenosis with cilostazol: a metaanalysis. Angiology. 2016;67(6):549–555. DOI: 10.1177/0003319715604768.
11. Іshiguro M., Mishiro K., Chen H. et al. Phosphodiesterase-III ingibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS One. 2010;5(12):5178. DOI: 10.1371/journal.pone.0015178.
12. De Franciscis S., Gallelli L., Battaglia L. et al. Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease. Int Wound J. 2015;12(3):250–253. DOI: 10.1111/iwj.12085.
13. Fujita Y., Lin J.X., Takahashi R., Tomimoto H. Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in stroke prone spontaneously hypertensive rats. Brain Res. 2008;1203:170–176.
14. Resnick K.A., Gordon I.L. Effects of cilostazol on arterial wound healing: a retrospective analysis. Ann Vasc Surg. 2014:28(6):1513–1521. DOI: 10.1016/j.avsg.2014.02.018.
15. Patent RU2549459C2 "Method of treating neuropathic trophic ulcers accompanying diabetic foot". Date of publication: 27.04.2015. Bull. 12.
16. Kotelnikov G.P., Shpigel A.S. Evidence-based medicine. Evidence-based medical practice. Samara: SamSMU; 2000 (in Russ.).
17. Voronin A.S. Development and experimental and clinical basis for the use of herval medicinal wound coverings in local treatment of wounds and wound infection of skin and soft tissues: thesis. Volgograd; 2012 (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать